The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
Here's a roundup of top developments in the biotech space over the last 24 hours:
Medtronic Announces Regulatory Approval, Launch In Japan Of Micra AV Transcatheter Pacing System
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received approval from Japan's Ministry of Health, Labor and Welfare for the sale and reimbursement of the
BTIG Downgrades Medtronic to Neutral
BTIG analyst Sean Lavin downgrades Medtronic (NYSE:MDT) from Buy to Neutral.
Morgan Stanley Downgrades Medtronic to Equal-Weight, Lowers Price Target to $120
Morgan Stanley analyst Cecilia Furlong downgrades Medtronic (NYSE:MDT) from Overweight to Equal-Weight and lowers the price target from $145 to $120.
Piper Sandler Downgrades Medtronic to Neutral, Lowers Price Target to $110
Piper Sandler analyst Matt O'Brien downgrades Medtronic (NYSE:MDT) from Overweight to Neutral and lowers the price target from $152 to $110.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
(MDT) – Analyzing Medtronic PLC. Ordinary Shares’s Short Interest
Medtronic PLC. Ordinary Shares's (NYSE:MDT) short percent of float has risen 8.96% since last its last report. The company recently reported that it has 9.84 million shares sold short, which is 0.73% of all regular shares that are available for trading.
Analyst Ratings For Medtronic
Medtronic (NYSE:MDT) has observed the following analyst ratings within the last quarter:
Credit Suisse Maintains Outperform on Medtronic, Lowers Price Target to $142
Credit Suisse analyst Matt Miksic maintains Medtronic (NYSE:MDT) with a Outperform and lowers the price target from $146 to $142.